

Press Release

Lonza Prices CHF 250 Million Five-Year Straight Bond with a 0.125% Coupon

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR SECURITIES. THE OFFER OF THE INSTRUMENT OUTLINED HEREIN IS PROHIBITED OR RESTRICTED IN VARIOUS JURISDICTIONS INCLUDING THE UNITED STATES, THE EUROPEAN ECONOMIC AREA AND THE UK.

Basel, 12 October 2016 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 250 million straight-bond issue. The bond has a maturity of five years and an annual coupon of 0.125%. The issuer is Lonza Swiss Finance Ltd, Basel, and the bond will be guaranteed by Lonza.

Lonza will apply for the listing of the bond on the SIX Swiss Exchange. The proceeds of the bond will be used for partial refinancing of the InterHealth acquisition and general financing purposes.

Key Data:

Issue Size Five-Year Bond:	CHF 250 million
Expected Payment Date:	1 November 2016
Maturity:	1 November 2021
Issue Price:	100.037%
Redemption Price:	100%
Coupon:	0.125% p.a.
Joint Lead Managers:	Credit Suisse AG, Zürich; Commerzbank AG; Zürcher Kantonalbank

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Lonza Group Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
www.lonza.com

Press Release

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Group Ltd	Lonza Group Ltd	Lonza Group Ltd
Head Investor Relations	Head Corporate Communications	Head External Communications
Dirk Oehlers	Dominik Werner	Constance Ward
Tel +41 61 316 8540	Tel +41 61 316 8798	Tel +41 61 316 8840
Fax +41 61 316 9540	Fax +41 61 316 9540	Fax +41 61 316 9840
dirk.oehlers@lonza.com	dominik.werner@lonza.com	constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.